INDIA LIVE DESKNIFTY 50:23,140.50(+0.34%)SENSEX:73,895.74(+0.43%)
RDU Global
🇮🇳
Home/Topics/Companies & Institutions/Vyvgart
Back to Newsroom
🏢Organization Dossier

Vyvgart

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

3 Stories Indexed
Last Updated: Just Now
Verified Entity Intelligence
Global Markets & Equities 09 Oct 2026, 10:10 AM IST

Argenx Absorbs Celiac Trial Win as It Prepares Pivotal Push for $2.2 Billion Drug

Argenx is leaning into a promising phase 2 readout in celiac disease as it prepares a pivotal development run for its next major growth driver, a program the market has increasingly tied to a multibillion-dollar commercial opportunity. The update comes as investors also weigh a separate setback in another late-stage autoimmune study, underscoring both the promise and volatility of the company’s expanding immunology pipeline.

By RDU Global Wire4 min read
Global Markets & EquitiesJust now (11:54 AM IST)

Treasury Yields Hold Steady as Traders Brace for Critical U.S. Jobs Data

U.S. Treasury yields were little changed as investors positioned cautiously ahead of the next major labor-market reading, a report that could shape expectations for Federal Reserve policy and the direction of global risk assets. With markets already sensitive to any sign of cooling growth or sticky inflation, the jobs release has become the immediate focal point for rates traders, equity investors, and currency desks alike.

5 min readRead →
Global Markets & Equities09 Oct 2026, 06:38 PM IST

Argenx Digests Celiac Disease Win as $2.2 Billion Vyvgart Bet Faces New Scrutiny

Argenx is trying to turn a phase 2 celiac disease win into momentum for its flagship Vyvgart franchise, even as investors reassess the drugmaker after a late-stage setback in Sjögren’s disease. The company’s latest data point supports a broader autoimmune expansion strategy, but the market is now weighing whether the pipeline can absorb the blow from a discontinued study and still justify the valuation attached to its multibillion-dollar ambitions.

5 min readRead →

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside Vyvgart: